Clinical Trial Search

Primary: Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 6 — 2.5; 5.0 Percentage of Participants — p=0.021

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.5; 96.2; 97.3 Percentage of participants…

Primary: Number of Treatment Emergent Adverse Events (TEAEs) — 909; 954; 269 Number of events

Primary: Change in HbA1c (Glycosylated Haemoglobin) From Baseline — -1.32; -1.61; -0.55 percentage of glycosylated haemoglobin — p=<0.0001

Primary: Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response — 37; 48 Participants — p=0.397

Primary: Percentage of Participants Who Discontinued Due to Adverse Event — 4.65; 4.96 Percentage of Participants — p=1

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD) — -2.74; -4.83; -4.62 Migraine Headache Days per Month — p=<.001

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days — -2.28; -4.29; -4.18 Migraine Headache Days per Month — p=<.001

Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40

Primary: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 — 6.8; 37.3 percentage of participants — p=<0.001

Primary: Time to Complete Healing of Reference Ulcer — 77; 69 days — p=0.246

Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722

Primary: Incidence of Clinical Malaria Episodes — 2.49; 2.00 episodes

Primary: Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose — 11.8; 19.2; 21.2 percentage of participants — p=0.0023

Primary: PRNT GMT — 110.7; 100.5; 117.2; 1.0 Titer